Your browser doesn't support javascript.
loading
Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains.
Rabani, Vahideh; Lagoutte-Renosi, Jennifer; Series, Jennifer; Valot, Benoit; Xuereb, Jean-Marie; Davani, Siamak.
Afiliación
  • Rabani V; EA 3920 Université Bourgogne Franche-Comté, F-25000 Besancon, France.
  • Lagoutte-Renosi J; EA 3920 Université Bourgogne Franche-Comté, F-25000 Besancon, France.
  • Series J; Laboratoire de Pharmacologie Clinique et Toxicologie-CHU de Besançon, F-25000 Besancon, France.
  • Valot B; Inserm UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31100 Toulouse, France.
  • Xuereb JM; UMR CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besancon, France.
  • Davani S; Inserm UMR1048, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), F-31100 Toulouse, France.
Int J Mol Sci ; 21(21)2020 Oct 29.
Article en En | MEDLINE | ID: mdl-33138025
Platelet protease-activated receptor 1 (PAR1) is a cell surface G-protein-coupled receptor (GPCR) that acts as a thrombin receptor promoting platelet aggregation. Targeting the PAR1 pathway by vorapaxar, a PAR1 antagonist, leads to a reduction in ischemic events in cardiovascular patients with a history of myocardial infarction or with peripheral arterial disease. In platelets, specialized microdomains highly enriched in cholesterol act as modulators of the activity of several GPCRs and play a pivotal role in the signaling pathway. However, their involvement in platelet PAR1 function remains incompletely characterized. In this context, we aimed to investigate whether activation of PAR1 in human platelets requires its localization in the membrane cholesterol-rich microdomains. Using confocal microscopy, biochemical isolation, and proteomics approaches, we found that PAR1 was not localized in cholesterol-rich microdomains in resting platelets, and only a small fraction of the receptor relocated to the microdomains following its activation. Vorapaxar treatment increased the level of PAR1 at the platelet surface, possibly by reducing its endocytosis, while its colocalization with cholesterol-rich microdomains remained weak. Consistent with a cholesterol-dependent activation of Akt and p38 MAP kinase in thrombin receptor-activating peptide (TRAP)-activated platelets, the proteomic data of cholesterol-rich microdomains isolated from TRAP-activated platelets showed the recruitment of proteins contributing to these signaling pathways. In conclusion, contrary to endothelial cells, we found that PAR1 was only weakly present in cholesterol-rich microdomains in human platelets but used these microdomains for efficient activation of downstream signaling pathways following TRAP activation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plaquetas / Agregación Plaquetaria / Colesterol / Proteoma / Microdominios de Membrana / Receptor PAR-1 Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plaquetas / Agregación Plaquetaria / Colesterol / Proteoma / Microdominios de Membrana / Receptor PAR-1 Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2020 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza